Cargando…

Reply: Comment on alemtuzumab and inclusion body myositis

Detalles Bibliográficos
Autores principales:	Dalakas, Marinos C., Rakocevic, Goran, Schmidt, Jens, McElroy, Beverly, Harris-Love, Michael O., Shrader, Joseph A., Levy, Ellen W., Dambrosia, James
Formato:	Texto
Lenguaje:	English
Publicado:	Oxford University Press 2010
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2859147/ https://www.ncbi.nlm.nih.gov/pubmed/19892769 http://dx.doi.org/10.1093/brain/awp276

Ejemplares similares

Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis
por: Dalakas, Marinos C., et al.
Publicado: (2009)

Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM
por: Schmidt, Karsten, et al.
Publicado: (2016)

Inclusion Body Myositis Treated with Alemtuzumab
por: Sá, Juliana, et al.
Publicado: (2019)

Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study
por: Sparks, Susan, et al.
Publicado: (2007)

Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis
por: Kosmidis, Michalis L., et al.
Publicado: (2019)

Quantitative clinical and autoimmune assessments in stiff person syndrome: evidence for a progressive disorder
por: Rakocevic, Goran, et al.
Publicado: (2019)

Obinutuzumab, a potent anti–B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy
por: Rakocevic, Goran, et al.
Publicado: (2018)

Guillain-Barré syndrome: The first documented COVID-19–triggered autoimmune neurologic disease: More to come with myositis in the offing
por: Dalakas, Marinos C.
Publicado: (2020)

A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
por: Aouad, Patrick, et al.
Publicado: (2018)

Immune and myodegenerative pathomechanisms in inclusion body myositis
por: Keller, Christian W., et al.
Publicado: (2017)

Update in inclusion body myositis
por: Machado, Pedro, et al.
Publicado: (2013)

Genetics in inclusion body myositis
por: Rothwell, Simon, et al.
Publicado: (2017)

A protocol to develop clinical guidelines for inclusion‐body myositis
por: Jones, Katherine L., et al.
Publicado: (2016)

Development and validation of a Bayesian survival model for inclusion body myositis
por: Capkun, Gorana, et al.
Publicado: (2019)

The Low Prevalence of Inclusion Body Myositis in an Outpatient Rheumatology Myositis Cohort
por: Edigin, Ehizogie, et al.
Publicado: (2020)

Reply to Dr. Hendricks’ Review: The Pathology of Typhoid Fever
por: McElroy, Z. C.
Publicado: (1868)

Detecting dysphagia in inclusion body myositis
por: Cox, F. M., et al.
Publicado: (2009)

Alemtuzumab
por: Tridente, Giuseppe
Publicado: (2013)

Inflammasome in Skeletal Muscle: NLRP3 Is an Inflammatory Cell Stress Component in Inclusion Body Myositis
por: Kummer, Karsten, et al.
Publicado: (2023)

Inclusion body myositis--a case report.
por: Park, S. H., et al.
Publicado: (1996)

Inclusion-Body Myositis Associated with Alzheimer's Disease
por: Levacic, Danijela, et al.
Publicado: (2013)

Inclusion body myositis associated with Sjögren’s syndrome
por: Misterska-Skóra, Maria, et al.
Publicado: (2012)

Proteomic study of sporadic inclusion body myositis
por: Li, Ke, et al.
Publicado: (2014)

Ongoing Developments in Sporadic Inclusion Body Myositis
por: Machado, Pedro M., et al.
Publicado: (2014)

17. Inclusion body myositis associated with SLE
por: Jones, Catrin M, et al.
Publicado: (2018)

Survival and associated comorbidities in inclusion body myositis
por: Naddaf, Elie, et al.
Publicado: (2021)

Dysphagia as the Presenting Symptom for Inclusion Body Myositis
por: Esteban, Marcus Juan, et al.
Publicado: (2021)

Sporadic inclusion body myositis: the genetic contributions to the pathogenesis
por: Gang, Qiang, et al.
Publicado: (2014)

Mitochondrial and inflammatory changes in sporadic inclusion body myositis
por: Rygiel, Karolina A., et al.
Publicado: (2015)

Emerging therapeutic options for sporadic inclusion body myositis
por: Alfano, Lindsay N, et al.
Publicado: (2015)

Inclusion body myositis – pathomechanism and lessons from genetics
por: Murnyák, Balázs, et al.
Publicado: (2015)

Clinical, Histological, and Immunohistochemical Findings in Inclusion Body Myositis
por: de Camargo, Leonardo Valente, et al.
Publicado: (2018)

CYLD dysregulation in pathogenesis of sporadic inclusion body myositis
por: Yamashita, Satoshi, et al.
Publicado: (2019)

Inclusion body myositis in a patient with rheumatoid arthritis
por: Tariq, Mohammad, et al.
Publicado: (2018)

Sarcoidosis: Is It a Possible Trigger of Inclusion Body Myositis?
por: Zakaria, Ali, et al.
Publicado: (2017)

Beevor’s sign in a case of inclusion body myositis
por: Sarraf, Payam, et al.
Publicado: (2021)

Inclusion body myositis: Update on the diagnostic and therapeutic landscape
por: Naddaf, Elie
Publicado: (2022)

Epidemiology, Survival, and Clinical Characteristics of Inclusion Body Myositis
por: Lindgren, Ulrika, et al.
Publicado: (2022)

Inclusion Body Myositis and Neoplasia: A Narrative Review
por: Damian, Laura, et al.
Publicado: (2022)

COVID-19-Induced Sporadic Inclusion Body Myositis
por: Dalal, Fazal, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_81sg9uu1eudrcotu23fe7lqqm2